Zoetis (ZTS) Change in Accured Expenses (2014 - 2026)
Zoetis (ZTS) reported Change in Accured Expenses of -$234.0 million for Q1 2026, down 13.59% year-over-year from -$270.8 million in Q1 2025, and down 365.91% quarter-over-quarter from $88.0 million in Q4 2025.
Zoetis (ZTS) Change in Accured Expenses (2014 - 2026) Analysis & Trends
Zoetis (ZTS) has 13 years of Change in Accured Expenses data on file, last reported at -$234.0 million in Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at -$234.0 million, down 13.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $57.0 million (up 72.73% YoY), and the FY2025 annual result was $85.0 million, down 25.44% from the prior year.
- Change in Accured Expenses eased to -$234.0 million in Q1 2026 per ZTS's latest filing, from $88.0 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $124.0 million in Q3 2024 and troughed at -$234.0 million in Q1 2026.
- A 5-year average of -$8.7 million and a median of $32.0 million in 2023 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses tumbled 208.33% in 2022, then surged 825.0% in 2024.
- A 5-year view of Change in Accured Expenses shows it stood at $47.0 million in 2022, then jumped by 100.0% to $94.0 million in 2023, then decreased by 17.02% to $78.0 million in 2024, then gained by 12.82% to $88.0 million in 2025, then tumbled by 365.91% to -$234.0 million in 2026.
- Business Quant data shows ZTS's Change in Accured Expenses at -$234.0 million in Q1 2026, $88.0 million in Q4 2025, and $101.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Accured Exp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | -144.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | -234.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | -12.70 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | -14.30 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 4.89 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 23.00 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 10.02 Mn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | 14.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -234.00 Mn |
| Mar 31, 2026 | -234.00 Mn |
| Dec 31, 2025 | 88.00 Mn |
| Dec 31, 2025 | 88.00 Mn |
| Sep 30, 2025 | 101.00 Mn |
| Sep 30, 2025 | 101.00 Mn |
| Jun 30, 2025 | 102.00 Mn |
| Jun 30, 2025 | 102.00 Mn |
| Mar 31, 2025 | -206.00 Mn |
| Mar 31, 2025 | -206.00 Mn |
| Dec 31, 2024 | 78.00 Mn |
| Dec 31, 2024 | 78.00 Mn |
| Sep 30, 2024 | 124.00 Mn |
| Sep 30, 2024 | 124.00 Mn |
| Jun 30, 2024 | 37.00 Mn |
| Jun 30, 2024 | 37.00 Mn |
| Mar 31, 2024 | -125.00 Mn |
| Mar 31, 2024 | -125.00 Mn |
| Dec 31, 2023 | 94.00 Mn |
| Dec 31, 2023 | 94.00 Mn |